Nexsen lays out clinical plans for rapid Strep B test development

Nexsen Biotech plans to evaluate the sensitivity and specificity of its rapid point of care for Group B streptococci (GBS), StrepSure, in a clinical trial.

The Australian company has partnered with Northern Health in Australia to conduct clinical trials of StrepSure, said Nexsen’s CEO Thomas Hanley in an interview with Clinical Trials Arena.